SCHEMBL1128579

SCHEMBL1128579

CC(C)c1noc([C@H]2CC[C@@H](NNC(=O)OC(C)(C)C)CC2)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EPHX2 P34913 1/20 0.42
▸ CHRM4 P08173 1/20 0.40
▸ CCR5 P51681 1/20 0.38
▸ KCNH2 Q12809 1/20 0.38
▸ HCRTR1 O43613 1/20 0.37
▸ HCRTR2 O43614 1/20 0.37
▸ SMYD3 Q9H7B4 3/20 0.36
▸ CNR2 P34972 1/20 0.34
▸ LIPG Q9Y5X9 1/20 0.34
▸ SCN9A Q15858 1/20 0.34
▸ FABP4 P15090 2/20 0.34
▸ FABP5 Q01469 2/20 0.34
▸ GAA P10253 2/20 0.33
▸ HSD11B1 P28845 1/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ NPC1 O15118 1/20 0.32
▸ RAB9A P51151 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ SMO Q99835 1/20 0.32
▸ GPR119 Q8TDV5 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1128582 1.00 EPHX2 (0.42) EPHX2CHRM4CCR5KCNH2HCRTR1
SCHEMBL4355370 1.00 EPHX2 (0.42) EPHX2CHRM4CCR5KCNH2HCRTR1
SCHEMBL1128755 0.79 ALDH1A1 (0.51) EPHX2CHRM4CCR5KCNH2HCRTR1
SCHEMBL12069832 0.75 EPHX2 (0.51) EPHX2CHRM4CCR5KCNH2CNR2
SCHEMBL9963213 0.74 CNR2 (0.49) EPHX2CHRM4CCR5KCNH2HCRTR1
SCHEMBL2074992 0.74 GAA (0.51) GAAMEN1NPC1RAB9AKMT2A
SCHEMBL1128456 0.72 CNR2 (0.42) EPHX2CHRM4CCR5KCNH2HCRTR1
SCHEMBL12400788 0.72 CA1 (0.36) CHRM4CCR5KCNH2SMYD3CNR2
SCHEMBL3882891 0.72 CA1 (0.36) CHRM4CCR5KCNH2SMYD3CNR2
SCHEMBL3882887 0.72 CA1 (0.36) CHRM4CCR5KCNH2SMYD3CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188098-B2 GPR119 receptor agonists HOFFMANN-LA ROCHE INC. (US) 2012-05-29 — — US disclosed
US-8188098-B2 GPR119 receptor agonists HOFFMANN-LA ROCHE INC. (US) 2012-05-29 — — US disclosed
US-8188098-B2 GPR119 receptor agonists HOFFMANN-LA ROCHE INC. (US) 2012-05-29 — — US disclosed
EP-2283019-A1 GPR119 RECEPTOR AGONISTS F. Hoffmann-La Roche AG (CH) 2011-02-16 — — EP disclosed
WO-2009141238-A1 GPR119 RECEPTOR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-11-26 — — WO disclosed
US-20090286812-A1 GPR119 Receptor Agonists ERICKSON SHAWN DAVID 2009-11-19 — — US disclosed
US-20090286812-A1 GPR119 Receptor Agonists ERICKSON SHAWN DAVID 2009-11-19 — — US disclosed
US-20090286812-A1 GPR119 Receptor Agonists ERICKSON SHAWN DAVID 2009-11-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286812-A1 GPR119 Receptor Agonists GPR119, GPR27, GPR139 EPHX2 1539/4885CHRM4 544/4885CCR5 659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback